209 related articles for article (PubMed ID: 11717596)
1. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
Bittl JA; Chaitman BR; Feit F; Kimball W; Topol EJ
Am Heart J; 2001 Dec; 142(6):952-9. PubMed ID: 11717596
[TBL] [Abstract][Full Text] [Related]
2. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.
Bittl JA; Strony J; Brinker JA; Ahmed WH; Meckel CR; Chaitman BR; Maraganore J; Deutsch E; Adelman B
N Engl J Med; 1995 Sep; 333(12):764-9. PubMed ID: 7643883
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators.
Bittl JA; Feit F
Am J Cardiol; 1998 Oct; 82(8B):43P-49P. PubMed ID: 9809891
[TBL] [Abstract][Full Text] [Related]
4. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
[TBL] [Abstract][Full Text] [Related]
5. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.
Bittl JA; Ahmed WH
Am J Cardiol; 1998 Oct; 82(8B):50P-56P. PubMed ID: 9809892
[TBL] [Abstract][Full Text] [Related]
6. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
Carswell CI; Plosker GL
Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions.
Shah PB; Ahmed WH; Ganz P; Bittl JA
J Am Coll Cardiol; 1997 Nov; 30(5):1264-9. PubMed ID: 9350925
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
9. Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.
Seybert AL
Pharmacotherapy; 2002 Jun; 22(6 Pt 2):112S-118S. PubMed ID: 12064568
[TBL] [Abstract][Full Text] [Related]
10. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
Antman EM; McCabe CH; Braunwald E
Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin for patients with acute coronary syndromes.
Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
[TBL] [Abstract][Full Text] [Related]
12. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
[TBL] [Abstract][Full Text] [Related]
14. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
[TBL] [Abstract][Full Text] [Related]
16. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
[TBL] [Abstract][Full Text] [Related]
17. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
Lincoff AM; Kleiman NS; Kottke-Marchant K; Maierson ES; Maresh K; Wolski KE; Topol EJ
Am Heart J; 2002 May; 143(5):847-53. PubMed ID: 12040347
[TBL] [Abstract][Full Text] [Related]
19. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
20. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
